Investor Presentaiton

Sartorius Group Lab Products & Services: Below strong Q1 2023 but recovery ongoing except for China; investment activity widely soft Order intake € in millions -6.2% cc -8.2% 189 173 Sales revenue Underlying EBITDA & margin € in millions € in millions -15.3% cc -17.1% 208 173 -24.4% 55 41 26,3 24,0 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 ■ Ol below Q1 2023 but above Q4 2023; strong recurring business; particularly dynamic development in Americas Sales revenue below strong Q1 2023 but above Q3 and Q4 2023 Underlying EBITDA margin impacted by lower volumes and product mix. 11 41 SARTORIUS

View entire presentation